WuXi Biologics is trading 5.35% down at HK$46.04, with the October 16 move occurring amid broader market pressure and no clear company-specific catalyst identified in available reporting. - In the prior session, Hong Kong shares faced pressure from hotter-than-expected U.S. inflation concerns and selling across technology and biotechnology stocks, including WuXi Biologics. - Recent ESG-index inclusion was positive but does not explain the decline.